{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:22Z","timestamp":1791665962339,"version":"4.3.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Gemcitabine plus Capecitabine (Gem\/Cape) is a frequently adopted second line chemotherapy for metastatic adrenocortical carcinoma (ACC), but only a minority of patients is destined to obtain a clinical benefit. The identification of baseline predictive factors of efficacy is relevant. We retrospectively analyzed clinical data from 50 consecutive patients with metastatic progressing ACC treated between 2011 and 2019. Patients received intravenous Gemcitabine and oral Capecitabine on a metronomic schedule. Previous mitotane therapy was maintained. Clinical benefit (partial response + stable disease) at 4 months was 30%, median progression-free survival (PFS) and disease-specific survival (DSS) from Gem\/Cape start were 3 and 8 months, respectively. Among clinical variables evaluated before the start of Gem\/Cape, presence of ECOG performance status \u22651 [HR 6.93 95% confidence interval (CI) 0.03\u20130.54, p.004] and neutrophil-to-lymphocyte ratio (NLR) \u22655 [HR 3.88, 95% (CI) 0.81\u20130.90, p.003] were independent indicators of poor PFS at multivariate analysis. Conversely, surgery of primary tumor, the presence of lung or lymph-node metastases, blood mitotane level, anemia, and the Advanced Lung cancer Inflammation index (ALI) failed to be independently associated. This study confirms that the Gem\/Cape schedule is modestly active in heavily pretreated ACC patients (28% received at least two previous chemotherapy lines). NLR and performance status (PS) are easily available clinical parameters that are helpful to identify patients not likely to derive significant advantage from Gem\/Cape chemotherapy.<\/jats:p>","DOI":"10.3389\/fendo.2021.624102","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T06:15:58Z","timestamp":1614147358000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Salvatore","family":"Grisanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Dalla","family":"Volta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Domenico","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-013-0049-2","article-title":"Management of adrenal cancer: a 2013 update","volume":"37","author":"Terzolo","year":"2014","journal-title":"J Endocrinol Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1055\/a-0715-1946","article-title":"Advanced Adrenocortical Carcinoma - What to do when First-Line Therapy Fails","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf291","article-title":"Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma","volume":"13","author":"Baudin","year":"2002","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008377915129","article-title":"Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-2564","article-title":"Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine","volume":"93","author":"Quinkler","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01029","article-title":"Management of patients with adrenal cancer: recommendations of an international consensus conference","volume":"12","author":"Schteingart","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.3390\/cancers11101500","article-title":"Health-Related Quality of Life in Adrenocortical Carcinoma","volume":"11","author":"Steenaard","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/0277-9536(92)90053-s","article-title":"A study of quality of life in cancer patients receiving palliative chemotherapy","volume":"35","author":"Payne","year":"1992","journal-title":"Soc Sci Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Lib\u00e9","year":"2015","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-13-158","article-title":"Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review","volume":"13","author":"Jafri","year":"2013","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00918","article-title":"Predictors of Survival in Adrenocortical Carcinoma: An Analysis From the National Cancer Database","volume":"103","author":"Tella","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.coemr.2019.07.07","article-title":"Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures","volume":"8","author":"Grisanti","year":"2019","journal-title":"Curr Opin Endocrine Metab Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1530\/eje-19-0570","article-title":"Activity and safety of temozolomide in advanced adrenocortical carcinoma patients","volume":"181","author":"Cosentini","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/eje-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23982","article-title":"Neutrophil-lymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma","volume":"112","author":"Bagante","year":"2015","journal-title":"J Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12894-017-0240-4","article-title":"The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis","volume":"17","author":"Mochizuki","year":"2017","journal-title":"BMC Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1518-3","article-title":"Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy","volume":"54","author":"Suzuki","year":"2019","journal-title":"J\u00a0Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20329","article-title":"Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer","volume":"91","author":"Walsh","year":"2005","journal-title":"J Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.1981.tb00171.x","article-title":"Influence of in vivo hydrocortisone on some human blood lymphocyte subpopulations. I. Effect on natural killer cell activity","volume":"13","author":"Onsrud","year":"1981","journal-title":"Scand J Immunol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.624102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T06:16:01Z","timestamp":1614147361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.624102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":27,"alternative-id":["10.3389\/fendo.2021.624102"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.624102","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"article-number":"624102"}}